145 related articles for article (PubMed ID: 22147537)
1. Hepatitis C virus-related cryoglobulinemic vasculitis: emerging trends in therapy.
St Clair EW
Arthritis Rheum; 2012 Mar; 64(3):604-8. PubMed ID: 22147537
[No Abstract] [Full Text] [Related]
2. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis.
Sneller MC; Hu Z; Langford CA
Arthritis Rheum; 2012 Mar; 64(3):835-42. PubMed ID: 22147444
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis.
De Vita S; Quartuccio L; Isola M; Mazzaro C; Scaini P; Lenzi M; Campanini M; Naclerio C; Tavoni A; Pietrogrande M; Ferri C; Mascia MT; Masolini P; Zabotti A; Maset M; Roccatello D; Zignego AL; Pioltelli P; Gabrielli A; Filippini D; Perrella O; Migliaresi S; Galli M; Bombardieri S; Monti G
Arthritis Rheum; 2012 Mar; 64(3):843-53. PubMed ID: 22147661
[TBL] [Abstract][Full Text] [Related]
4. [Kidney involvement in mixed cryoglobulinemia: which treatment?].
Cacoub P
Presse Med; 2012 Mar; 41(3 Pt 1):254-9. PubMed ID: 22192935
[TBL] [Abstract][Full Text] [Related]
5. L11. Hepatitis C virus mixed cryoglobulinemia vasculitis: therapeutic options.
Cacoub P; Terrier B; Saadoun D
Presse Med; 2013 Apr; 42(4 Pt 2):523-7. PubMed ID: 23453499
[No Abstract] [Full Text] [Related]
6. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis.
Saadoun D; Delluc A; Piette JC; Cacoub P
Curr Opin Rheumatol; 2008 Jan; 20(1):23-8. PubMed ID: 18281853
[TBL] [Abstract][Full Text] [Related]
7. [Successful rituximab therapy of HCV-cryoglobulinemic vasculitis with severe ulcerative and necrotic lesions of the skin].
Ignatova TM; Chernova OA; Gaĭdasheva EV
Klin Med (Mosk); 2012; 90(5):64-6. PubMed ID: 22993956
[TBL] [Abstract][Full Text] [Related]
8. Long-term remission with rituximab in a patient with severe hepatitis C virus-induced mixed cryoglobulinemia.
Fortea-Ormaechea JI; Lozano-Maya M; Adán-Merino L; Barrio-Antoranz J; Martín-Chavarri S; Corchete-Prats E; Martínez-Acebes E; Aldeguer-Martínez M
Rev Esp Enferm Dig; 2013 Sep; 105(8):490-3. PubMed ID: 24274448
[TBL] [Abstract][Full Text] [Related]
9. Update in rheumatology: evidence published in 2012.
Deodhar A
Ann Intern Med; 2013 Jun; 158(12):903-6. PubMed ID: 23580081
[No Abstract] [Full Text] [Related]
10. The dilemma of treating hepatitis C virus-associated cryoglobulinemia.
Roccatello D; Fenoglio R; Sciascia S
Curr Opin Rheumatol; 2019 Sep; 31(5):499-504. PubMed ID: 31090590
[TBL] [Abstract][Full Text] [Related]
11. Treatment of cryoglobulinemia associated peripheral neuropathy with rituximab.
Cai FZ; Ahern M; Smith M
J Rheumatol; 2006 Jun; 33(6):1197-8. PubMed ID: 16755669
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of tocilizumab in rituximab-refractory cryoglobulinemia vasculitis.
Cohen C; Mekinian A; Saidenberg-Kermanac'h N; Stirnemann J; Fenaux P; Gherardi R; Fain O
Ann Rheum Dis; 2012 Apr; 71(4):628-9. PubMed ID: 22121135
[No Abstract] [Full Text] [Related]
13. [Current possibilities for treatment for hepatitis C virus-induced cryoglobulinemic vasculitis and B-cell lymphoma].
Ignatova TM; Mukhin NA
Ter Arkh; 2012; 84(11):81-8. PubMed ID: 23252255
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and risk of rituximab in type II mixed cryoglobulinemia: a significant case report.
Massari M; Catania A; Magnani G
Dig Liver Dis; 2007 Sep; 39 Suppl 1():S134-5. PubMed ID: 17936216
[No Abstract] [Full Text] [Related]
15. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients.
Terrier B; Saadoun D; Sène D; Sellam J; Pérard L; Coppéré B; Karras A; Blanc F; Buchler M; Plaisier E; Ghillani P; Rosenzwajg M; Cacoub P
Arthritis Rheum; 2009 Aug; 60(8):2531-40. PubMed ID: 19644879
[TBL] [Abstract][Full Text] [Related]
16. [Successful treatment of severe HCV-cryoglobulinemic vasculitis with the use of CD20 monoclonalantibodies and antiviral agents].
Ignatova TM; Chernova OA; Burnevich EZ; Milovanova SIu
Klin Med (Mosk); 2014; 92(8):62-4. PubMed ID: 25790700
[TBL] [Abstract][Full Text] [Related]
17. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis.
Lamprecht P; Lerin-Lozano C; Merz H; Dennin RH; Gause A; Voswinkel J; Peters SO; Gutzeit O; Arlt AC; Solbach W; Gross WL
Ann Rheum Dis; 2003 Dec; 62(12):1230-3. PubMed ID: 14644867
[TBL] [Abstract][Full Text] [Related]
18. Essential mixed cryoglobulinemia type III with leukocytoclastic vasculitis: remission by rituximab.
Baerlecken NT; Schmidt RE
Clin Rheumatol; 2013 Mar; 32 Suppl 1():S19-20. PubMed ID: 20213127
[TBL] [Abstract][Full Text] [Related]
19. [Twenty-seven years' activities of the French vasculitis study group (FVSG)].
Guillevin L
Rev Med Interne; 2007 Dec; 28 Suppl 4():S263-5. PubMed ID: 18029060
[No Abstract] [Full Text] [Related]
20. New insights in cryoglobulinemic vasculitis.
Silva F; Pinto C; Barbosa A; Borges T; Dias C; Almeida J
J Autoimmun; 2019 Dec; 105():102313. PubMed ID: 31383568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
